Global pharmaceutical company Allergan plc announced earlier today that its merger agreement with Pfizer has been terminated by mutual agreement.
In connection with the termination of the merger agreement, Pfizer has reportedly agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.
In its official press statement, Allergan reiterated its compelling standalone growth profile and strategy following the announced termination of the combination of the two companies, stating the company was positioned to drive strong, sustainable growth powered by leading franchises, new potential blockbuster product launches and unmatched pipeline.
Click here to read the full press release.